Marché européen du diagnostic du cancer du sein – Tendances et prévisions du secteur jusqu’en 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché européen du diagnostic du cancer du sein – Tendances et prévisions du secteur jusqu’en 2030

  • Medical Devices
  • Publish Reports
  • Feb 2023
  • Europe
  • 350 Pages
  • Nombre de tableaux : 272
  • Nombre de figures : 35

Europe Breast Cancer Diagnostics Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
Dollars américains 2,041.29
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché européen du diagnostic du cancer du sein, par type de test (imagerie, biopsie, test génomique , test sanguin et autres), type (carcinome canalaire in situ, carcinome canalaire invasif, cancer du sein inflammatoire et cancer du sein métastatique), utilisateur final (hôpitaux, cliniques, instituts de recherche et universitaires, centres de diagnostic et autres), canal de distribution (appel d'offres direct, vente au détail et autres), tendances et prévisions de l'industrie jusqu'en 2030.

Marché européen du diagnostic du cancer du sein

Analyse et perspectives du marché européen du diagnostic du cancer du sein

Le cancer du sein est la maladie la plus courante dans la population, survenant principalement chez les femmes atteintes de maladies prolifératives. Le cancer du sein se développe principalement dans les tissus mammaires. Les symptômes du cancer du sein comprennent des bosses dans le sein, une différence de taille et de forme des seins, un écoulement des mamelons et des plaques rouges irritées et squameuses sur la peau. L'incidence du cancer du sein chez les femmes augmente à chaque fois que la croissance du marché du cancer du sein augmente avec la croissance des médicaments. Méthodes avancées de diagnostic du cancer du sein avec des techniques développées. Amélioration des technologies développées dans le cancer du sein en augmentant l'efficacité, la précision, l'efficience, la fiabilité et la rapidité des résultats et en améliorant la détection des troubles. Fonctionnalités avancées pour détecter le cancer en moins de temps. Le cancer est détecté à un stade précoce, ce qui aide les patients à récupérer plus rapidement, empêche les cellules cancéreuses de se propager à d'autres parties du corps et les traite avec de nouveaux médicaments sur le marché. L'augmentation du dépistage et de l'imagerie des tumeurs stimulera le marché du cancer du sein. Cela élargit le marché du cancer du sein avec un nombre croissant de patients chaque année, et le taux de guérison du cancer du sein augmente. Soutien gouvernemental en augmentant la disponibilité de nouveaux projets de développement de médicaments et en augmentant l’efficacité et l’efficience du traitement et l’intégration de nouveaux médicaments dans le domaine médical.

Marché européen du diagnostic du cancer du sein

Marché européen du diagnostic du cancer du sein

Cependant, le coût élevé des traitements de diagnostic du cancer et le manque de professionnels qualifiés sont les facteurs qui freinent la croissance du marché.

Data Bridge Market Research analyse que le marché européen du diagnostic du cancer du sein devrait atteindre la valeur de 2 041,29 millions USD d'ici 2030, à un TCAC de 8,7 % au cours de la période de prévision. Le type de test représente le segment de type de diagnostic le plus important du marché en raison de l'augmentation du nombre de patientes atteintes du cancer du sein et des avancées technologiques dans le traitement du cancer du sein en Europe. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Années historiques

2021 (personnalisable pour 2020-2016)

Unités quantitatives

Chiffre d'affaires en millions USD, volumes en unités, prix en USD

Segments couverts

By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others)  Distribution Channel (Direct Tender, Retail Sales, and Others).

Countries Covered

Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Ireland and Rest of Europe.

Market Players Covered

The major companies which are dealing in the market are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc., and Abacus ALS, among others.

Europe Breast Cancer Diagnostics Market Definition

Breast cancer is a disease in which the uncontrolled growth of malignant cells in the breast tissue occurs more often in women than in men. Breast cancer is the uncontrolled cell division of breast cells, which are the most common cells in the mammary glands and ducts. Some symptoms of breast cancer include a lump or lump in the breast, bloody discharge from the nipple and a change in the shape of the nipple or breast. Breast cancer treatment depends on the stage of cancer. Its treatment consists of chemotherapy, radiation therapy, hormone therapy, and surgery.

Breast cancer is another type of cancer that is more common in women than in men. A number of the symptoms of the sickness hold bleeding secretion from the reproductive organ, a lump or block within the breast, and variations in the texture or form of the breast or nipple. Breast cancer treatment depends on the stage of cancer. In addition, its treatment includes radiotherapy, therapy, hormone therapy and surgery. Early detection of carcinoma is essential for the effective treatment of the disease. Early detection of the disease also leads to better outcomes, including many treatment options, better survival and better quality of life. Increasing pressure and demand for new forms of treatment or methods of treatment are due to the rapidly increasing spread of diseases.

Europe Breast Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Launch of technologically advanced diagnosis & therapeutics to aid growth

Breast cancer is the most common disease in the population, occurring mainly in women with proliferative disease. Breast cancer develops in the breast tissues. Symptoms of breast cancer include lumps in the breast, differences in the size and shape of the breast, discharge from the nipples, and itchy, scaly red patches on the skin. This disease spreads in body with increasing symptoms such as bone pain, swollen lymph nodes, difficulty in breathing and many others. Increasing research and development with new technologies and treatments developed for breast cancer will significantly contribute to market growth.

Moreover, Technological advances in imaging are creating new opportunities for improvements in both screening and early detection. One technology advance is 3-D mammography, also called breast tomosynthesis. This procedure takes images from different angles around the breast and builds them into a 3-D-like image.

In the recent times, several advancements in technology is changing the fate of cancer diagnostics, as mentioned above some of the recent advancements, several other technologies are currently under trial phase which are on the limit of changing the process of breast cancer diagnostics. These technological advancements in the field are acting as a major drivers for Europe breast cancer diagnostics market.

  • Increasing prevalence of breast cancer

One of the major factors driving the growth of the Europe market is the increasing prevalence of breast cancer worldwide, which is expected to lead to a large number of patients in need of accurate and effective treatment options. Breast cancer is one of the most common cancers in the world, and better diagnostics are expected to increase the number of patients diagnosed in the future.

In addition, the growing demand for preventive care and early treatment has led to many cancer screenings, which would also increase the number of patients with a high need for treatment during the forecast period.

Thus, increasing prevalence of breast cancer leads to more diagnosis of cases and hence it is expected to drive the market growth during the forecast period.

Restraint

  • Adverse effects of breast cancer therapeutics

Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat. By the time symptoms appear, cancer may have begun to spread. Several screening tests are used for detecting breast cancers which include breast magnetic resonance imaging, diagnostic mammogram, biopsy etc. Although these test are considered to be standard for diagnosing breast cancer, they have their associated risks which include false-negative results, false-positive results, and side effects such as undue psychological stress, excessive radiation exposure, and a serious risk of tumor rupture and spread of cancerous cells.

Opportunity

  • Initiatives taken by the government

Government is focusing on increasing the initiative for breast cancer treatments with advanced techniques to improve the health of patients. Providing he number of insurances, such as benefits, has been increased so that ordinary people can choose treatment and take advantage of available medicines and treatments to improve their quality of life. In developing countries such as China and India, the government has launched several programs and initiatives to raise awareness about the disease. This has greatly increased the demand for breast cancer diagnosis and disease management therapies. Increasing mergers and acquisitions between pharmaceutical companies and government agencies are among the main trends in the Europe breast cancer market.

Rates of new breast cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame. As the breast cancer patient rate is increasing, the use of treatments and advanced technologies for the diagnosis of cancer will increase, which is an opportunity for market growth.

Challenge

  • Lack of diagnostic infrastructure

Non-communicable diseases such as breast cancer and other types of cancer have now been recognized by the United Nations and WHO as a major public health crisis. Cancer is the biggest part of this problem, and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approach and outcomes between high income countries and low and middle income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps, and lack of awareness among the lay and medical community.

Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.

Post-COVID-19 Impact on Europe Breast Cancer Diagnostics Market

The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.

Recent Developments

  • En novembre 2022, Koninklijke Philips NV a annoncé le lancement européen d'une solution d'échographie portable compacte de nouvelle génération lors de la réunion annuelle de la Radiological Society of North America (RSNA) afin d'apporter la qualité diagnostique associée aux systèmes d'échographie sur chariot haut de gamme à un plus grand nombre de patients. Elle est portable et polyvalente avec une bonne qualité d'image ou de performances. Elle est compatible avec les systèmes d'échographie Philips Affiniti et la sonde EPIQ. Cela a aidé l'entreprise à élargir son portefeuille de produits.
  • En novembre 2022, Siemens Healthineers et Atrium Health, un important fournisseur de soins de santé à but non lucratif connu pour ses programmes de soins pédiatriques, oncologiques et cardiaques, ont annoncé un partenariat de valeur pluriannuel1. Cet accord stratégique vise à améliorer l'accès aux soins dans la zone de service d'Atrium Health dans le sud-est des États-Unis, à améliorer l'équité en matière de santé et à accroître la mobilité économique. Atrium Health acquiert pour plus de 140 millions de dollars d'équipements et d'appareils auprès de Siemens Healthineers, notamment des technologies d'imagerie avancées, de radio-oncologie et de robotique endovasculaire de précision. Cela a aidé l'entreprise à développer ses activités.

Portée du marché européen du diagnostic du cancer du sein

Le marché européen du diagnostic du cancer du sein est segmenté en type de test, type, utilisateur final et canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.

MARCHÉ EUROPÉEN DU DIAGNOSTIC DU CANCER DU SEIN, PAR TYPE DE TEST

  • IMAGERIE
  • BIOPSIE
  • TEST GÉNOMIQUE
  • ANALYSE DE SANG
  • AUTRES

Sur la base du type de test, le marché européen du diagnostic du cancer du sein est segmenté en imagerie, biopsie, test génomique, tests sanguins et autres.

MARCHÉ EUROPÉEN DU DIAGNOSTIC DU CANCER DU SEIN, PAR TYPE

  • CARCINOME CANALAIRE IN SITU
  • CARCINOME CANALAIRE INVASIF
  • CANCER INFLAMMATOIRE DU SEIN
  • CANCER DU SEIN MÉTASTATIQUE

Sur la base du type, le marché européen du diagnostic du cancer du sein est segmenté en carcinome canalaire in situ, carcinome canalaire invasif, cancer du sein inflammatoire et cancer du sein métastatique.

MARCHÉ EUROPÉEN DU DIAGNOSTIC DU CANCER DU SEIN, PAR UTILISATEUR FINAL

  • HÔPITAUX
  • CLINIQUES
  • INSTITUTS DE RECHERCHE ET D'ENSEIGNEMENT
  • CENTRES DE DIAGNOSTIC
  • AUTRES

Sur la base de l'utilisateur final, le marché européen du diagnostic du cancer du sein est segmenté en hôpitaux, cliniques, instituts de recherche et universitaires, centres de diagnostic et autres.

MARCHÉ EUROPÉEN DU DIAGNOSTIC DU CANCER DU SEIN, PAR CANAL DE DISTRIBUTION

  • APPEL D'OFFRES DIRECT
  • VENTES AU DÉTAIL
  • AUTRES

Sur la base du canal de distribution, le marché européen du diagnostic du cancer du sein est segmenté en appels d'offres directs, ventes au détail et autres.

Marché du diagnostic du cancer du sein

Analyse/perspectives régionales du marché européen du diagnostic du cancer du sein

Le marché européen du diagnostic du cancer du sein est analysé et des informations sur la taille du marché sont fournies sur le type de test, le type, l'utilisateur final et le canal de distribution.

Les pays couverts par ce rapport de marché sont l'Allemagne, la France, le Royaume-Uni, l'Italie, la Russie, l'Espagne, les Pays-Bas, la Suisse, la Belgique, la Turquie, l'Irlande et le reste de l'Europe.

En 2023, le Royaume-Uni domine la région Europe en raison de la production de masse de médicaments de diagnostic du cancer du sein et de la demande croissante des marchés émergents et de l'expansion des industries de traitement du cancer.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du diagnostic du cancer du sein en Europe

Le paysage concurrentiel du marché européen du diagnostic du cancer du sein fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché européen du diagnostic du cancer du sein.

Certains des principaux acteurs opérant sur le marché européen du diagnostic du cancer du sein sont F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips NV, FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc. et Abacus ALS.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

5 EPIDEMIOLOGY

6 INDUSTRIAL INSIGHTS

7 REGULATORY FRAMEWORK

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH

8.1.2 INCREASING PREVALENCE OF BREAST CANCER

8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH

8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER

8.2 RESTRAINTS

8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS

8.2.2 HIGH COST OF THE IMAGING SYSTEMS

8.3 OPPORTUNITIES

8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT

8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS

8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER

8.4 CHALLENGES

8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE

8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER

9 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING

9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES

9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)

9.2.1.2 ANALOG MAMMOGRAPHY

9.2.1.3 3D BREAST TOMOSYNTHESIS

9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)

9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)

9.2.1.6 POSITRON EMISSION MAMMOGRAPHY

9.2.1.7 OTHERS

9.2.2 NON-IONIZING IMAGING TECHNOLOGIES

9.2.2.1 OPTICAL IMAGING

9.2.2.2 BREAST ULTRASOUND

9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)

9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)

9.2.2.5 BREAST THERMOGRAPHY

9.2.3 BIOPSY

9.2.3.1 SURGICAL BIOPSY

9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY

9.2.3.3 CORE NEEDLE BIOPSY

9.2.3.4 IMAGE-GUIDED BIOPSY

9.2.3.5 SENTINEL LYMPH NODE BIOPSY

9.2.4 GENOMIC TEST

9.2.4.1 MOLECULAR TESTING

9.2.4.1.1 PD-L1

9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)

9.2.4.1.3 NTRK GENE FUSIONS

9.2.4.1.4 PI3KCA GENE MUTATION

9.2.4.2 MAMMAPRINT

9.2.4.3 ONCOTYPE DX

9.2.4.4 OTHERS

9.3 BLOOD TEST

9.4 OTHERS

10 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

10.1 OVERVIEW

10.2 INVASIVE DUCTAL CARCINOMA

10.3 DUCTAL CARCINOMA IN SITU

10.4 INFLAMMATORY BREAST CANCER

10.5 METASTATIC BREAST CANCER

11 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 DIAGNOSTICS CENTERS

11.4 CLINICS

11.5 RESEARCH & ACADEMIC INSTITUTES

11.6 OTHERS

12 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 RUSSIA

13.1.4 ITALY

13.1.5 U.K.

13.1.6 SPAIN

13.1.7 TURKEY

13.1.8 NETHERLANDS

13.1.9 BELGIUM

13.1.10 SWITZERLAND

13.1.11 IRELAND

13.1.12 REST OF EUROPE

14 EUROPE BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 HOLOGIC, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 SIEMENS HEALTHCARE GMBH

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 F. HOFFMANN- LA ROCHE LTD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 KONINKLIJKE PHILIPS N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENTS

16.6 ABACUS ALS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 BD

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 COMPANY SHARE ANALYSIS

16.7.4 PRODUCT PORTFOLIO

16.7.5 RECENT DEVELOPMENTS

16.8 BIOCEPT, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 BIOMÉRIEUX

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 BIO-RAD LABORATORIES, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CEPHEID

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 EXACT SCIENCES CORPORATION

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 COMPANY SHARE ANALYSIS

16.12.4 PRODUCT PORTFOLIO

16.12.5 RECENT DEVELOPMENTS

16.13 FUJIFILM CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 GENERAL ELECTRIC

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 ILLUMINA, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 MYRIAD GENETICS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 NANOSTRING.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.17.5 RECENT DEVELOPMENT

16.18 ONCOSTEM.

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 PROVISTA DIAGNOSTICS.

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 THERMO FISHER SCIENTIFIC INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Liste des tableaux

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020)

TABLE 2 MORTALITY RATE OF BREAST CANCER (2020)

TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER

TABLE 4 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 9 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 10 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 11 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 14 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 17 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 19 EUROPE BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 22 EUROPE INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 EUROPE DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 EUROPE INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 EUROPE METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 27 EUROPE HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 EUROPE DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 EUROPE CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 EUROPE RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 33 EUROPE DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 EUROPE RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 37 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 39 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 40 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 41 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 42 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 43 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 45 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 47 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 49 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 50 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 51 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 52 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 GERMANY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 56 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 57 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 58 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 59 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 60 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 62 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 63 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 65 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 66 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 67 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 68 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 69 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 71 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 72 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 FRANCE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 76 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 77 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 79 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 80 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 82 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 83 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 84 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 85 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 86 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 88 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 89 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 90 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 91 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 92 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 RUSSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 96 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 97 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 99 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 100 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 102 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 103 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 105 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 106 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 108 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 109 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 113 ITALY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 114 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 115 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 116 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 117 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 119 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 120 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 122 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 123 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 125 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 126 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 128 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 129 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 131 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 132 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 133 U.K. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 134 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 136 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 137 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 139 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 140 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 141 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 142 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 143 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 144 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 145 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 146 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 147 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 148 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 149 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 150 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 151 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 152 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 153 SPAIN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 154 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 156 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 157 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 159 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 160 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 161 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 162 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 163 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 164 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 165 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 166 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 168 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 169 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 170 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 171 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 172 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 TURKEY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 176 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 177 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 179 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 180 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 181 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 182 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 183 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 184 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 185 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 186 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 188 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 189 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 190 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 191 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 192 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 NETHERLANDS IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 194 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 196 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 197 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 198 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 199 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 200 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 201 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 202 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 203 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 204 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 205 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 206 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 208 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 209 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 210 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 211 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 212 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 BELGIUM IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 214 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 215 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 216 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 217 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 219 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 220 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 221 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 222 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 223 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 225 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 226 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 227 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 228 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 229 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 230 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 231 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 232 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 233 SWITZERLAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 234 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 235 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 236 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 237 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 238 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 239 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 240 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 242 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 243 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 244 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 245 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 246 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 247 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 248 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 249 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 250 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 251 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 252 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 253 IRELAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 254 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 255 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 256 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 257 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 258 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 259 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 260 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 262 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 263 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 264 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 265 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 266 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 267 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 268 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 269 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 270 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 271 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 272 REST OF EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 EUROPE BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BREAST CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE BREAST CANCER DIAGNOSTICS MARKET

FIGURE 14 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022

FIGURE 15 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 16 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE

FIGURE 18 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022

FIGURE 19 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION)

FIGURE 20 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030)

FIGURE 21 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE

FIGURE 22 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022

FIGURE 23 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)

FIGURE 24 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)

FIGURE 25 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022

FIGURE 27 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 28 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 29 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 EUROPE BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 31 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 32 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 EUROPE BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 35 EUROPE BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Europe Breast Cancer Diagnostics Market size will be worth USD 2,041.29 million by 2030 during the forecast period.
The Europe Breast Cancer Diagnostics Market growth rate is 8.7% during the forecast period.
The Rising Demand for Mental Health Services and Rising Need for Radiological Services are the growth drivers of the Europe Breast Cancer Diagnostics Market.
The type, delivery mode, application, and end user are the factors on which the Europe Breast Cancer Diagnostics Market research is based.
The major companies in the Europe Breast Cancer Diagnostics Market are everon, Ada Health GmbH, Avi Medical GmbH, arztkonsultation ak GmbH, TeleClinic GmbH, MedKitDoc, Kry International AB, Telemedicine Clinic, Doktorse Nordic AB, ORTIVUS AB, Nia Health GmbH, Medloop Ltd., Heartbeat Labs Gmbh, and Konsilmed.